Titlebook: DNA Topoisomerases and Cancer; Yves Pommier Book 2012 Springer Science+Business Media, LLC 2012 Tyrosyl-DNA-Phosphodiesterase.Ubiquitin.an

易于出錯(cuò)

謙虛的人

CAMP

https://doi.org/10.1007/978-1-4614-0323-4Tyrosyl-DNA-Phosphodiesterase; Ubiquitin; antigens; camptothecins; transcriptional stress

catagen

顧客

焦慮

Introduction and Historical Perspective,Topo III, and Topo IV) and eukaryotic cells (Topo IB, Topo II, Topo III). Later on, new families and subfamilies of DNA topoisomerases were discovered in Archaea, the third domain of life (reverse gyrase, Topo V, Topo VI), challenging the prokaryote/eukaryote dichotomy. DNA topoisomerases are now cl

多節(jié)

,Topoisomerases and Carcinogenesis: Topoisomerase IIIα and BLM,Lengthening of Telomeres) in cells lacking telomerase activity. The recent implication of some variants of . and . genes in cancer risk in the general population underline the importance of the BLM-Top3α complex in maintaining genomic stability and preventing cancer.

手榴彈

Topoisomerase I Inhibitors: Chemical Biology,thecins include edotecarin, an indolocarbazole that results in DNA C/T-G cleavage compared with T-G/A for camptothecins. Indenoisoquinolines identified as Top1 inhibitors by the “NCI 60-cell line COMPARE” analysis are in clinical development. Dibenzonaphthyridinone Top1 inhibitors have undergone ext

Hormones

Topoisomerase II Inhibitors: Chemical Biology,that may have clinical promise. Although currently used Top2 targeting drugs act by generating enzyme-mediated DNA damage, catalytic inhibition remains a tantalizing possibility. Since current results suggest that topoisomerase IIβ, one of the two mammalian isoforms of topoisomerase II, is important

易于出錯(cuò)

Topoisomerase I Inhibitors: Current Use and Prospects,also provides a glimpse at other Top1 inhibitors under development. Advances in our understanding of Top1 action covered elsewhere in this volume, and reasons for selectivity and resistance will undoubtedly extend the clinical applications of these drugs.